Overview
Hepatitis C is an infection caused by the hepatitis C virus. The virus spreads through contact with infected blood – like during some kinds of sex without a condom or by sharing or reusing needles. Pregnant women with hepatitis C (HSV) can pass the virus to their newborn during birth. The symptoms of acute HCV may not be noticed but can include fever, joint pain, nausea and vomiting, clay-colored stool, and/or dark or “tea-colored” urine. Most people cannot fight off the virus without treatment and will develop chronic HCV. Chronic HCV does not usually show symptoms, but yellow skin, stomach swelling, or other signs of liver failure should be reported to a doctor right away. If not treated, chronic HCV will damage the liver and can lead to serious problems like cirrhosis, liver failure, or liver cancer. Every adult should be tested for HCV at least once or more often if they have a higher risk for HCV – like injecting drugs, getting a tattoo in prison, or being pregnant. No vaccines are available to prevent HCV, but chronic HCV can be cured up to 95% of the time. Treatment can last 8-24 weeks.
Drug Therapies
-
Epclusa (sofosbuvir/velpatasvir)
Epclusa (sofosbuvir/velpatasvir) is a combination of two antiviral medications approved to treat chronic hepatitis C infections in all patients regardless of hepatitis C genotype.Manufacturer:GileadRoute of Administration:OralSite of Care:OutpatientWebsite:Approved Indication:
treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis, with compensated cirrhosis, or with decompensated cirrhosis for use in combination with ribavirin
Conditions:
- Chronic Viral Hepatitis C
Therapeutic Area:
- Gastroenterology
- Hepatology
- Infectious Disease
-
Harvoni (ledipasvir/sofosbuvir)
Harvoni (ledipasvir/sofosbuvir) is a combination of two antiviral medications approved to treat chronic hepatitis C infections in patients with hepatitis C genotypes 1, 4, 5, or 6 regardless of concomitant cirrhosis.Manufacturer:GileadRoute of Administration:OralSite of Care:OutpatientWebsite:Approved Indication:
treatment of chronic hepatitis C virus in adults and pediatric patients 3 years of age and older with either
- genotype 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis
- genotype 1 with decompensated cirrhosis in combination with ribavirin
- genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis in combination with ribavirin
Conditions:
- Chronic Viral Hepatitis C
Therapeutic Area:
- Gastroenterology
- Hepatology
- Infectious Disease
-
Mavyret (glecaprevir/pibrentasvir)
Mavyret (glecaprevir/pibrentasvir) is a combination of two antiviral medications approved to treat chronic hepatitis C infections in patients with or without compensated cirrhosis regardless of hepatitis C genotype.Manufacturer:AbbVieRoute of Administration:OralSite of Care:OutpatientWebsite:Approved Indication:
- treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis
- treatment of adult and pediatric patients 3 years of age and older with HCV genotype 1 infection who previously have been treated with a regimen containing an HCV NS5A or an NS3/4A protease inhibitor, but not both
Conditions:
- Chronic Viral Hepatitis C
Therapeutic Area:
- Gastroenterology
- Hepatology
- Infectious Disease
-
ribavirin
Ribavirin is an antiviral medication used in combination with at least two direct-acting antivirals for the treatment of hepatitis C in patients with decompensated cirrhosis.Manufacturer:MiscRoute of Administration:OralSite of Care:OutpatientWebsite:Enrollment Forms:Synergen Prescription FormApproved Indication:
chronic viral hepatitis C in combination with other antiviral(s)
Conditions:
- Chronic Viral Hepatitis C
Therapeutic Area:
- Gastroenterology
- Infectious Disease
- Hepatology
-
Vosevi (Sofosbuvir / Velpatasvir / Voxilaprevir)
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) is a combination of three antiviral medications approved to treat chronic hepatitis C infections in patients who have previously failed therapy with another direct-acting antiviral.Manufacturer:GileadRoute of Administration:OralSite of Care:OutpatientWebsite:Approved Indication:
treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis who have
- genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor
- genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor
Conditions:
- Chronic Viral Hepatitis C
Therapeutic Area:
- Gastroenterology
- Infectious Disease
- Hepatology
-
Zepatier (elbasvir/grazoprevir)
Zepatier (elbasvir/grazoprevir) is a combination of two antiviral medications approved to treat chronic hepatitis C infection in patients with hepatitis C genotype 1 or 4 and without cirrhosis or with compensated cirrhosis.Manufacturer:MerckRoute of Administration:OralSite of Care:OutpatientWebsite:Approved Indication:
treatment of adults with chronic HCV genotype 1 or 4 infection without cirrhosis or with compensated cirrhosis in combination with ribavirin for certain patient populations
Conditions:
- Chronic Viral Hepatitis C
Therapeutic Area:
- Gastroenterology
- Infectious Disease
- Hepatology
Resources
Understanding a diagnosis can feel overwhelming. These resources link to well-established organizations, for in-depth education, research, and support.
Stay Connected
Get the latest news and updates